Health Care·Life Sciences Tools & Services·$174.6B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $5.76 | N/A | +23.37% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $5.76 | N/A | +23.37% |
| Revenue | N/A | N/A | N/A |
Tone: Cautiously Optimistic
Overall, management conveyed a positive outlook regarding current demand. However, they refrained from offering specific guidance for the upcoming quarters.
Management highlighted strong demand for their products.
They expressed confidence in their operational efficiency.
No specific guidance was provided for future quarters.
Thermo Fisher Scientific's earnings report shows a strong performance in EPS, exceeding expectations significantly. The stock reacted positively, rising by 0.65%. Investors may view the strong EPS as a sign of the company's resilience and operational strength, although the lack of revenue data and future guidance leaves some uncertainty.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
KIMBERLY CLARK CORP
Oct 25, 2021